Mumbai Explores WHO-Endorsed Tongue Swab TB Test Pilot

Mumbai Explores WHO-Endorsed Tongue Swab TB Test Pilot | Quick Digest
Mumbai's civic body, BMC, is considering a pilot project to use WHO-recommended tongue swab molecular tests for TB detection, aiming to simplify diagnosis, especially for children and those unable to produce sputum. This initiative follows recent global guidelines and addresses India's high TB burden.

Key Highlights

  • BMC considering pilot for new WHO-endorsed TB tongue swab tests.
  • WHO recently recommended near point-of-care molecular tests with tongue swabs.
  • Tongue swabs offer easier, non-invasive TB sample collection, especially for children.
  • India, particularly Mumbai, faces a significant tuberculosis burden.
  • New molecular tests, including Indian-made ones, are more affordable at $3.5.
  • The initiative aims to bridge diagnostic gaps and accelerate TB elimination efforts.
The Brihanmumbai Municipal Corporation (BMC) is contemplating launching a pilot project in Mumbai to evaluate the effectiveness of tongue swab samples for detecting tuberculosis (TB). This move comes approximately a month after the World Health Organization (WHO) issued new recommendations for near point-of-care (NPOC) molecular tests, explicitly endorsing the use of easy-to-collect tongue swab samples to streamline and broaden access to TB testing. The proposal is significant for India, which shoulders a disproportionately large share of the global TB burden. The WHO South-East Asia Region, where India is a key country, accounts for around 34-45% of the world's annual TB incidence. India alone contributes approximately 26-28% of global new TB cases, making it the epicenter of the disease. Mumbai, in particular, has been identified as one of the high-density TB hubs globally, registering 54,390 TB patients in 2022, with 8% having drug-resistant TB. The city has a history of pioneering new detection methods, including an AI-backed X-ray pilot project a few years ago to improve early diagnosis. The traditional method of diagnosing pulmonary TB typically involves collecting sputum, a mucus sample coughed up from deep within the lungs. However, many patients, especially children and those with HIV, struggle to produce adequate sputum samples, leading to diagnostic delays and difficulties. Tongue swabs offer a less invasive and easier alternative, which could significantly improve case detection, particularly in vulnerable populations. Dr. Daksha Shah, BMC executive health officer, highlighted that collecting tongue swabs would be simpler for certain patients, especially children. The WHO's updated policy, announced on February 26, 2026, marks a major advancement. For the first time, it has approved NPOC molecular tests that can be utilized at the primary care level, even with tongue swabs. This makes testing more accessible and affordable, moving diagnostics beyond centralized laboratories to primary healthcare centers and communities. Dr. Madhukar Pai, a Canada-based epidemiologist and public health expert, called this new WHO policy a "big deal" in the fight against TB, emphasizing its potential to reach more people who cannot produce sputum. Studies have shown promising results for oral and tongue swabs in TB detection. A systematic review noted that while sensitivity varied (36% to 91% in adults, 5% to 42% in children), most studies reported specificity of over 90%. More recent research published in Clinical Infectious Diseases found saliva sensitivity at 90.5% and specificity at 95.8%, while oral swabs had 71.6% sensitivity and 99% specificity against sputum culture. The World Health Organization has recommended minimum diagnostic performance targets for non-sputum TB diagnostic tests of ≥80% sensitivity and ≥98% specificity. Crucially, these new molecular tests are also more affordable. Dr. Pai mentioned that the new test is available via the Global Drug Facility at approximately $3.5 per test, making it significantly more economical than previous molecular tests. Furthermore, Indian companies like Huwel and Molbio have products that fit into this new category of WHO-endorsed NPOC molecular tests, further enhancing India's capacity to scale up such innovations. The Truenat MTB Ultima test by Molbio Diagnostics, for instance, is specifically mentioned for its use with tongue swabs. Despite India's efforts, including the National TB Elimination Program (NTEP) aiming to eliminate TB by 2025, the region remains off track to meet the 'End TB' milestones. The introduction of easier and more affordable diagnostic tools like tongue swabs is expected to help close the existing diagnostic gaps and accelerate progress towards these ambitious targets. This pilot project by the BMC, if implemented, represents a proactive step in leveraging global scientific advancements to tackle a persistent public health challenge at a local level.

Frequently Asked Questions

What is the new method for TB detection being considered by BMC?

The BMC is considering a pilot project to use tongue swab samples for tuberculosis (TB) detection, a method recently recommended by the World Health Organization (WHO) as part of new near point-of-care (NPOC) molecular tests.

Why are tongue swabs considered an improvement over traditional TB tests?

Tongue swabs offer a non-invasive and easier way to collect samples, especially beneficial for children and individuals who find it difficult to produce sputum (mucus coughed from the lungs), which is the traditional method for TB diagnosis. This simplifies the testing process and expands access to diagnosis.

When did the WHO recommend the use of tongue swabs for TB testing?

The World Health Organization (WHO) updated its policy on February 26, 2026, to recommend new near point-of-care (NPOC) molecular tests for TB diagnosis, explicitly including the use of easy-to-collect tongue swab samples.

How accurate and affordable are these new tongue swab tests?

While accuracy can vary, studies show promising results with high specificity (over 90%) and good sensitivity for molecular tests on oral samples. The new WHO-endorsed tests are also more affordable, costing around $3.5 per test through the Global Drug Facility.

What is India's role and burden regarding tuberculosis?

India bears a significant global TB burden, accounting for approximately 26-28% of all new cases worldwide, with cities like Mumbai identified as high-density TB hubs. The country is actively seeking innovative solutions, including adopting new diagnostic tools, to accelerate its TB elimination efforts.

Read Full Story on Quick Digest